PT/INR: used for monitoring warfarin therapy and assessing liver function. APTT: screens for intrinsic pathway defects and monitors unfractionated heparin. Fibrinogen: acute phase reactant and haemostasis marker — critically low in DIC. D-dimer: highly sensitive but non-specific for VTE; elevated in many conditions. Mixing studies: used to differentiate factor deficiency (corrects) from inhibitor (does not correct).
|
✓
Good practice The coagulation scientist checks the laboratory’s validated heparin nomogram — established by correlation with anti-Xa assay using this laboratory’s specific reagent and analyser. For this system, the therapeutic ratio range is 1.8 to 3.2 for a target anti-Xa of 0.3 to 0.7 U/mL. APTT ratio 2.1 corresponds to anti-Xa approximately 0.38 U/mL — within therapeutic range. This is reported with the anti-Xa equivalent.
|
✗
Poor practice The scientist uses the commonly cited therapeutic APTT ratio of 1.5 to 2.5 from a published guideline. Ratio 2.1 is within this range — reported as therapeutic. However, this laboratory’s reagent is sensitive to heparin. The actual therapeutic range for this system is 2.2 to 3.5. APTT ratio 2.1 in this system corresponds to anti-Xa 0.22 — subtherapeutic. The patient is under-anticoagulated and at risk of VTE recurrence.
|